Acta Med. 2017, 60: 5-11
https://doi.org/10.14712/18059694.2017.44
Anthelmintic Flubendazole and Its Potential Use in Anticancer Therapy
References
1. S, Moulder SL, Ueno NT, et al. Challenges and perspective of drug repurposing strategies in early phase clinical trials. Oncoscience 2015 Jun 30; 2(6): 576–80.
<https://doi.org/10.18632/oncoscience.173>
<PubMed>
2. JS, Liu JO. Recent Advances in Drug Repositioning for the Discovery of New Anticancer Drugs. International Journal of Biological Sciences 2014; 10(7): 654–63.
<https://doi.org/10.7150/ijbs.9224>
<PubMed>
3. MR, Yang L, Xie Q, Rajpal DK, Sanseau P, Agarwal P. Computational Drug Repositioning: From Data to Therapeutics. Clinical Pharmacology & Therapeutics 2013 Apr 1; 93(4): 335–41.
<https://doi.org/10.1038/clpt.2013.1>
4. CD, Geary TG. Flubendazole: a candidate macrofilaricide for lymphatic filariasis and onchocerciasis field programs. Expert Rev Anti Infect Ther 2011 May; 9(5): 497–501.
<https://doi.org/10.1586/eri.11.30>
5. YY, Jones SJ. Drug repositioning for personalized medicine. Genome Med. 2012 Mar 30; 4(3): 27.
<https://doi.org/10.1186/1755-8794-4-27>
<PubMed>
6. E. Mode of action of benzimidazoles. Parasitol Today (Regul Ed) 1990 Apr; 6(4): 112–5.
<https://doi.org/10.1016/0169-4758(90)90227-U>
7. CM, Gull K, Gutteridge WE, Pogson CI. The interaction of benzimidazole carbamates with mammalian microtobule protein. Biochem Pharmacol 1979 Sep 1; 28(17): 2680–2.
<https://doi.org/10.1016/0006-2952(79)90049-2>
8. Cooper GM. Microtubules 2000; Available from: http://www.ncbi. nlm.nih.gov/books/NBK9932/.
9. MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004 Apr; 4(4): 253–65.
<https://doi.org/10.1038/nrc1317>
10. N, Sanyal SN, Khera S. Effect of thiabendazole and fenbendazole on glucose uptake and carbohydrate metabolism in Trichuris globulosa. Vet Parasitol 1990 Mar; 35(3): 201–9.
<https://doi.org/10.1016/0304-4017(90)90055-G>
11. AC, Elissondo MC, Denegri GM. Flubendazole interferes with a wide spectrum of cell homeostatic mechanisms in Echinococcus granulosus protoscoleces. Parasitology International 2009 Sep; 58(3): 270–7.
<https://doi.org/10.1016/j.parint.2009.03.005>
12. Bossche HV, Thienpont D, Janssens PG. Chemotherapy of Gastrointestinal Helminths. Springer Science & Business Media 2012. 732 p.
13. M, Hendriks R, Heykants J, van den Bossche H. The pharmacokinetics of mebendazole and flubendazole in animals and man. Arch Int Pharmacodyn Ther 1982 Apr; 256(2): 180–91.
14. European Medicines Agency (online) – Committee for products for veterinary use – flubendazol – Summary report (July 2006). Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Maximum_Residue_Limits_Report/2009/11/WC500014292.pdf. (14 July 2016, date last accessed).
15. Institute for state control of veterinary biologicals and medicines – Summary of Product Characteristics – Flubenol® (online). Available at: http://www.uskvbl.cz. (14 July 2016, date last accessed).
16. QA, Galbraith EA, Baxter P. Oral absorption and bioavailability of fenbendazole in the dog and the effect of concurrent ingestion of food. J Vet Pharmacol Ther 1993 Jun; 16(2): 189–98.
<https://doi.org/10.1111/j.1365-2885.1993.tb00163.x>
17. L, Elissondo M, Bruni SS, Denegri G, Alvarez L, Lanusse C. Flubendazole in cystic echinococcosis therapy: pharmaco-parasitological evaluation in mice. Parasitol Int 2009 Dec; 58(4): 354–8.
<https://doi.org/10.1016/j.parint.2009.07.006>
18. Van Leemput L, Heykants J (1991). Flubendazole: concentrations in plasma and residues in edible tissues of pheasants after a 7-day treatment at 60 ppmin the feed. Unpublished report number R 17889/ FK1071. Submitted to FAO by Janssen Pharmaceutica, Beerse, Belgium.
19. G, Canton P, Gérard A, Dureux JB. Treatment of alveolar echinococcosis with flubendazole. Pharmacological study (author’s transl.). Pathol Biol 1982 Jun; 30(6): 452–7.
20. A, Estavoyer JM, Minazzi H, et al. Treatment of human alveolar echinococcosis with flubendazole. Clinical, morphological and immunological study. Gastroenterol Clin Biol 1984 Apr; 8(4): 314–20.
21. MH, Woon L, Almajd R, Akhter J, Bowery P, Morris DL. In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazole. Cancer Letters 2001 Apr 10; 165(1): 43–9.
<https://doi.org/10.1016/S0304-3835(01)00382-2>
22. V, Hanušová V, Staňková P, Knoppová K, Čáňová K, Skálová L. Antiproliferative effect of benzimidazole anthelmintics albendazole, ricobendazole, and flubendazole in intestinal cancer cell lines. Anticancer Drugs 2013 Oct; 24(9): 911–9.
<https://doi.org/10.1097/CAD.0b013e3283648c69>
23. MH, Akhter J, Wang L, Lu Y, Morris DL. Antitumor activity of albendazole against the human colorectal cancer cell line HT-29: in vitro and in a xenograft model of peritoneal carcinomatosis. Cancer Chemother Pharmacol 2004 Nov 23; 55(5): 425–32.
<https://doi.org/10.1007/s00280-004-0927-6>
24. A, Wangoo KT, Morris DL, Pourgholami MH. Epothilone-paclitaxel resistant leukemic cells CEM/dEpoB300 are sensitive to albendazole: Involvement of apoptotic pathways. Biochemical Pharmacology 2007 Aug 1; 74(3): 407–14.
<https://doi.org/10.1016/j.bcp.2007.05.006>
25. SWL, Badar S, Morris DL, Pourgholami MH. Potent inhibition of tubulin polymerisation and proliferation of paclitaxel-resistant 1A9PTX22 human ovarian cancer cells by albendazole. Anticancer Res 2009 Oct; 29(10): 3791–6.
26. D, Pompei P, Baldi C, Mazzoni G. Mebendazole inhibits growth of human adrenocortical carcinoma cell lines implanted in nude mice. Cancer Chemother Pharmacol 2008 Apr; 61(5): 809–17.
<https://doi.org/10.1007/s00280-007-0538-0>
27. J, Ramesh R, Chada S, Gomyo Y, Roth JA, Mukhopadhyay T. The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells. Mol Cancer Ther 2002 Nov; 1(13): 1201–9.
28. K, Williamson T, Wongkham S, Riggins GJ. Effect of the antiparasitic drug mebendazole on cholangiocarcinoma growth. Southeast Asian J Trop Med Public Health 2014 Nov; 45(6): 1264–70.
29. N, Rodriguez A, Osman I, Orlow SJ. Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells. Mol Cancer Res 2008 Aug; 6(8): 1308–15.
<https://doi.org/10.1158/1541-7786.MCR-07-2159>
30. P, Fryknäs M, Ågerup B, Larsson R. Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer. Journal of Cancer Research and Clinical Oncology 2013 Dec; 139(12): 2133–40.
<https://doi.org/10.1007/s00432-013-1539-5>
<PubMed>
31. P, Larsson R. Drug repositioning from bench to bedside: tumour remission by the antihelmintic drug mebendazole in refractory metastatic colon cancer. Acta Oncol 2014 Mar; 53(3): 427–8.
<https://doi.org/10.3109/0284186X.2013.844359>
32. LC, Soares BM, Pinheiro J de JV, Riggins GJ, Assumpção PP, Burbano RMR, et al. The anthelmintic drug mebendazole inhibits growth, migration and invasion in gastric cancer cell model. Toxicol In Vitro 2015 Dec; 29(8): 2038–44.
<https://doi.org/10.1016/j.tiv.2015.08.007>
33. PA, Hu J, Hurren R, et al. The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma. Blood 2010 Jun 10; 115(23): 4824–33.
<https://doi.org/10.1182/blood-2009-09-243055>
34. M, Agha B, Rothweiler F, et al. Identification of flubendazole as potential anti-neuroblastoma compound in a large cell line screen. Sci Rep 2015; 5: 8202.
<https://doi.org/10.1038/srep08202>
<PubMed>
35. Z-J, Luo X, Zhang W, et al. Flubendazole, FDA-approved anthelmintic, targets breast cancer stem-like cells. Oncotarget 2015 Mar 20; 6(8): 6326–40.
<https://doi.org/10.18632/oncotarget.3436>
<PubMed>
36. L, Guo M, Li J, et al. Systems biology-based discovery of a potential Atg4B agonist (Flubendazole) that induces autophagy in breast cancer. Mol Biosyst 2015 Nov; 11(11): 2860–6.
<https://doi.org/10.1039/C5MB00466G>
37. V, Hanušová V, Rudolf E, Čáňová K, Skálová L. Flubendazole induces mitotic catastrophe and senescence in colon cancer cells in vitro. J Pharm Pharmacol 2016 Feb; 68(2): 208–18.
<https://doi.org/10.1111/jphp.12503>
38. NA, Byron SA, Pollock PM, Orlow SJ. XIAP downregulation accompanies mebendazole growth inhibition in melanoma xenografts. Anticancer Drugs 2013 Feb; 24(2): 181–8.
<https://doi.org/10.1097/CAD.0b013e32835a43f1>
39. DL, Jourdan JL, Pourgholami MH. Pilot study of albendazole in patients with advanced malignancy. Effect on serum tumor markers/ high incidence of neutropenia. Oncology 2001; 61(1): 42–6.
<https://doi.org/10.1159/000055351>
40. MH, Szwajcer M, et al. Phase I clinical trial to determine maximum tolerated dose of oral albendazole in patients with advanced cancer. Cancer Chemother Pharmacol 2010 Feb; 65(3): 597–605.
<https://doi.org/10.1007/s00280-009-1157-8>
41. P, Bouche G, Meheus L, Sukhatme V, Sukhatme VP. Repurposing Drugs in Oncology (ReDO) – mebendazole as an anti-cancer agent. Ecancermedicalscience 2014 Jul 10; 8.
